Ryanair Holdings plc vs Zoetis Inc — how do they compare? Ryanair Holdings plc trades at $53.11 (market cap $27.11B), while Zoetis Inc trades at $74.36 (market cap $30.20B). The key difference: Ryanair Holdings plc and Zoetis Inc are close in size by market cap, and Zoetis Inc pays the higher dividend (2.9%). Which is the better fit depends on your goals — on Pluang, investors hold Ryanair Holdings plc for 72 Days and Zoetis Inc for 70 Days on average.
| RYAAY | ZTS | |
|---|---|---|
Market Cap | $27.11B | $30.20B |
Volume | 2,427,380 | 6,175,327 |
Sector | Industrials | Health |
52-Week High | $73.82 | $147.53 |
52-Week Low | $51.95 | $69.09 |
Typical Hold Time | 72 Days | 70 Days |
Enterprise Value | $24.18B | $37.76B |
Dividend Yield | 1.66% | 2.9% |
Signals from Pluang's Aura AI — not financial advice
RYAAY trades at $53.05, down 5.27% today, with a bearish technical signal from moving averages. The stock shows strong fundamentals with $13.95B revenue, 12.13% net margin, and attractive valuation at 13.43 P/E. Recent earnings show mixed results with Q2 2026 missing expectations, while analysts maintain 64.71% buy rating. The company faces headwinds from fuel costs and Boeing MAX 10 certification delays, but maintains robust cash flow and balance sheet strength.
RYAAY presents a compelling value opportunity with solid profitability and growth prospects, though near-term volatility from oil prices and operational challenges warrants caution. The stock's current discount to historical valuations combined with strong market position supports long-term upside potential for patient investors.
Zoetis (ZTS) trades at $74.38, up 3.96% in the last session, with a bullish technical signal and strong profitability metrics including a 71.67% gross margin and 27.69% net income margin. Recent earnings show mixed results, with a beat in Q2 2026 but a miss in Q1 2026, while Q3 2026 results are pending. The company maintains robust cash flow from operations of $2.90B in 2025 and a solid balance sheet with $1.99B in cash. Analyst consensus is a Buy with a $87.33 price target, though sentiment is tempered by near-term competitive pressures.
The outlook for ZTS is cautiously optimistic, supported by industry-leading margins and a diversified product portfolio, but faces headwinds from U.S. companion animal market weakness and increased competition. Investment opportunity lies in its undervalued P/E of 11.92 relative to growth potential, while risks include pricing erosion and volume declines. The stock's current level near resistance at $74 suggests potential for consolidation before further gains.
Trailing returns across standard periods
Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.
Read more on RYAAY →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →